Covetrus Partners with The Pet Fund® to Raise Money for Care of Diabetic Pets
Funds raised will provide diabetes medication for companion animals
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104005113/en/

Receiving a diagnosis of diabetes for a companion animal can be an emotional and financially overwhelming experience for pet owners. In recognition of National Diabetes Month, Covetrus® will donate
“We are pleased to have the support of
Diabetes is a disease caused by the lack of insulin that regulates blood-sugar levels. Historically, it has gone undiagnosed in companion animals, but the prevalence of diabetes has increased dramatically in recent years. Receiving a diagnosis of diabetes for a companion animal can be an emotional and financially overwhelming experience for pet owners. For some pet owners veterinary care for diabetes is beyond their means, leading to economic euthanasia or surrendering to a pet shelter.
“With regular veterinary care and education, diabetes management in companion animals is possible, and can result in greater quality of life for the pet,” said
About
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. For more information about
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005113/en/
Source:
Nicholas Jansen, Investor Relations
nicholas.jansen@covetrus.com
(207) 550-8106
Kiní Schoop, Public Relations
kini.schoop@covetrus.com
(207) 550-8018